Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Avacta Group PLC

AVCT.L ✗ NOT COMPLIANT ☆ Track — members

LSE · Healthcare · Biotechnology & Medical Research ·

UK Small Cap Analyst: BUY

Last Close

$0.87

▲ +0.00%

Market Cap $406.78M · Vol 266.92K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$406.78M

Small Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

+31.92%

YoY

RSI (14)

28.81

Momentum

Beta

1.35

vs Market

52W High

$1.24

30.83% below

52W Low

$0.62

40.37% above

Volume

266.92K

Avg 776.56K

P/B

103.17

Price-to-book

ROE

N/A

Return on equity

Free Float

97.02%

Public shares

Shariah Compliance8 STANDARDS

✗ Avacta Group PLC (AVCT.L) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AVCT.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.48%

-7.25%

-26.35%

+10.34%

YTD

+10.34%

+39.13%

-31.83%

-45.74%

Financials & Valuation

TTM · Annual

Total Revenue	$152.24K
Net Income	$-48,858,171.00
Revenue Growth (YoY)	+100.51%
Gross Margin	-1,031.86%
Operating Margin	-27,692.04%
Net Profit Margin	-32,092.04%
ROE	N/A
ROA · ROIC	-92.80% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2,051.99
P/B	103.17
P/FCF	N/A
EPS Growth	+31.92%
Outstanding Shares	471.33M

Technical Indicators

50-Day SMA	$0.95
200-Day SMA	$0.94
RSI (14)	28.81
Beta	1.35
52-Week High	$1.24
52-Week Low	$0.62

Volume Today	266.92K
Avg Daily Volume (30D)	776.56K
Relative Volume	0.34x
Volatility (10D)	24.09
Volatility (30D)	25.72
Free Float	97.02%

Analyst Consensus

BUY

Current Price $0.87

Mean Target $0.97

52W Low$0.62 52W High$1.24

Current

Target

$0.62 $1.24

Current Analyst target

+11.84% upside potential · 3 analysts

Identifiers

ExchangeLSE

FIGIBBG001SJRRZ8

ISINGB00BYYW9G87

CountryUnited Kingdom

Sub-IndustryBio Therapeutic Drugs

Earnings DateSep 28, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.